Phenotypic differences in tumor-associated macrophages between metastatic and primary sites of clear cell renal cell carcinoma.

Authors

null

Yuji Miura

Toranomon Hospital, Tokyo, Japan

Yuji Miura, Takanobu Motoshima, Nanako Wakigami, Natsuki Kusada, Toshikazu Okaneya, Toshimi Takano, Tomomi Kamba, Yoshihiro Komohara, Naoko Inoshita

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session B

Track

Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies

Sub Track

Biomarkers and Inflammatory Signatures

Citation

J Clin Oncol 36, 2018 (suppl 5S; abstr 105)

DOI

10.1200/JCO.2018.36.5_suppl.105

Abstract #

105

Poster Bd #

G2

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Genitourinary Cancers Symposium

<span>High expression of sialylated cancer-derived IgG and survival in metastatic clear cell renal cell carcinoma.</span>

High expression of sialylated cancer-derived IgG and survival in metastatic clear cell renal cell carcinoma.

First Author: Jie Wu

Poster

2016 Genitourinary Cancers Symposium

The loss of BAP1 protein expression in the first recurrence site of metastasis to predict prognosis.

The loss of BAP1 protein expression in the first recurrence site of metastasis to predict prognosis.

First Author: Yuji Miura

Poster

2024 ASCO Gastrointestinal Cancers Symposium

A phase 1 trial of combined MEK, STAT3 and PD-1 inhibition in metastatic pancreatic ductal adenocarcinoma (PDAC).

A phase 1 trial of combined MEK, STAT3 and PD-1 inhibition in metastatic pancreatic ductal adenocarcinoma (PDAC).

First Author: Peter Joel Hosein